• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

    2/9/24 5:07:50 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBTX alert in real time by email
    SC 13G/A 1 d687377dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

    (Amendment No. 3)

     

     

    NANOBIOTIX S.A.

    (Name of Issuer)

    Ordinary Shares, €0.03 nominal value per share

    (Title of Class of Securities)

    63009J107**

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    **

    This CUSIP number applies to the Issuer’s American Depositary Shares, evidenced by American Depositary Receipts, each representing one ordinary share of the Issuer.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 63009J107    13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Invus Public Equities, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Bermuda

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

      SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    2


    CUSIP No. 63009J107    13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Invus Public Equities Advisors, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

      SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    3


    CUSIP No. 63009J107    13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal International S.C.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

      SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    4


    CUSIP No. 63009J107    13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal International Management S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

      SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    5


    CUSIP No. 63009J107    13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal Group S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

      SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    6


    CUSIP No. 63009J107    13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Westend S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

      SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    7


    CUSIP No. 63009J107    13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Stichting Administratiekantoor Westend

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

      SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    8


    CUSIP No. 63009J107    13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Mr. Amaury Wittouck

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Belgium

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

      SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    9


    Item 1(a).

    Name of Issuer:

     

    Item 1(a).

    Name of Issuer:

    Nanobiotix S.A. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    60, rue de Wattignies, 75012 Paris, France

     

    Item 2(a).

    Name of Person Filing:

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

     

    Item 2(c).

    Citizenship:

     

    Item 2(c).

    Citizenship:

    (i) Invus Public Equities, L.P. (“Invus Public Equities”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Bermuda limited partnership

    (ii) Invus Public Equities Advisors, LLC (“Invus PE Advisors”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (iii) Artal International S.C.A. (“Artal International”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg limited partnership

    (iv) Artal International Management S.A. (“Artal International Management”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (v) Artal Group S.A. (“Artal Group”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (vi) Westend S.A. (“Westend”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (vii) Stichting Administratiekantoor Westend (the “Stichting”)

    Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands

    Citizenship: Netherlands foundation

    (viii) Mr. Amaury Wittouck

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Belgium

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”

     

    Item 2(d).

    Title of Class of Securities:

    Ordinary Shares, €0.03 nominal value per share (the “Shares”)

     

    Item 2(e).

    CUSIP Number:

    The CUSIP Number is 63009J107. This CUSIP applies to the American Depositary Shares (“ADSs”), evidenced by American Depositary Receipts, each representing one Share. No CUSIP has been assigned to the Shares.

     

    10


    Item 3.

    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

    This Item 3 is not applicable.

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    As of December 31, 2023, the Reporting Persons no longer beneficially own any Shares.

    (b) Percent of class:

    As of December 31, 2023, the Reporting Persons no longer beneficially own any Shares.

    (c) As of December 31, 2023, the number of shares as to which each of Invus Public Equities, Invus PE Advisors, Artal International, Artal International Management, Artal Group, Westend, the Stichting and Mr. Wittouck has:

    (i) Sole power to vote or to direct the vote:

    0

    (ii) Shared power to vote or to direct the vote:

    0

    (iii) Sole power to dispose or to direct the disposition of:

    0

    (iv) Shared power to dispose or to direct the disposition of:

    0

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of December 31, 2023 the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    This Item 6 is not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    This Item 7 is not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    This Item 8 is not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    This Item 9 is not applicable.

     

    Item 10.

    Certification.

    Each of the Reporting Persons hereby makes the following certification:

     

    11


    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    12


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 9, 2024

     

    INVUS PUBLIC EQUITIES, L.P.
    By:   INVUS PUBLIC EQUITIES ADVISORS, LLC,
    its general partner
    By:  

    /s/ Raymond Debbane

    Name:   Raymond Debbane
    Title:   President
    INVUS PUBLIC EQUITIES ADVISORS, LLC
    By:  

    /s/ Raymond Debbane

    Name:   Raymond Debbane
    Title:   President
    ARTAL INTERNATIONAL S.C.A.
    By:   ARTAL INTERNATIONAL
      MANAGEMENT S.A., its managing
      partner
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Managing Director
    ARTAL INTERNATIONAL MANAGEMENT S.A.
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Managing Director
    ARTAL GROUP S.A.
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Authorized Person
    WESTEND S.A.
    By:  

    /s/ Anne Goffard

    Name:   Anne Goffard
    Title:   Managing Director


    STICHTING
    ADMINISTRATIEKANTOOR
    WESTEND
    By:  

    /s/ Amaury Wittouck

    Name:   Amaury Wittouck
    Title:   Sole Member of the Board
    MR. AMAURY WITTOUCK
    By:  

    /s/ Amaury Wittouck

    Get the next $NBTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NBTX

    DatePrice TargetRatingAnalyst
    8/28/2024$12.00Buy
    Guggenheim
    12/8/2023$11.00Outperform
    Leerink Partners
    More analyst ratings

    $NBTX
    Leadership Updates

    Live Leadership Updates

    See more
    • NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

      PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) --  NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr Colette Shen, MD, PhD and Dr Ari Rosenberg, MD, and Dr Jeffrey Bockman, PhD, will moderate the event. The KOLs will join Dr Sebastien Paris, PhD, from the Company to provide an in-depth review of NBTXR3 and the data recently presented at the

      6/12/24 4:15:00 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

      PARIS and CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for half-year ending June 30, 2023, on Tuesday, September 26, 2023, after the close of the US market. This release will be followed by a conference on Wednesday, September 27, 2023, at 8:00 AM EDT / 2:00 PM CEST. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company's half-year results and provide an update on business activiti

      9/19/23 4:15:00 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

      PARIS and CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the appointment of Louis Kayitalire, MD, as chief medical officer. Dr. Kayitalire brings an exceptional biopharmaceutical industry track record with proven success in the research, development, registration, and commercialization of therapeutics in oncology. "We are pleased to welcome Dr. Kayitalire to our executive leadership team at this pivotal moment for the development and commercialization of potential first-in-class radioenhancer NBTXR3," sa

      9/5/23 4:15:00 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

      SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

      2/9/24 5:07:50 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

      SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

      2/8/24 8:27:02 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

      SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

      2/2/24 4:32:27 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    SEC Filings

    See more
    • SEC Form S-8 filed by Nanobiotix S.A.

      S-8 - Nanobiotix S.A. (0001760854) (Filer)

      5/14/25 4:37:40 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Nanobiotix S.A.

      6-K - Nanobiotix S.A. (0001760854) (Filer)

      5/14/25 6:00:07 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Nanobiotix S.A.

      6-K - Nanobiotix S.A. (0001760854) (Filer)

      5/12/25 11:35:02 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Nanobiotix with a new price target

      Guggenheim initiated coverage of Nanobiotix with a rating of Buy and set a new price target of $12.00

      8/28/24 7:51:18 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Nanobiotix with a new price target

      Leerink Partners initiated coverage of Nanobiotix with a rating of Outperform and set a new price target of $11.00

      12/8/23 8:52:29 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    Financials

    Live finance-specific insights

    See more
    • Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

      Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]Median Local Progression-Free Survival of 13.3 months from completion of radiationNotable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutational burden (cTMB) and LPFS and OSCA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS First patient injected in a new cohort that adds standard-of-care concurre

      5/5/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

      Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CESTNanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expa

      4/30/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

      Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerDisciplined financial strategy toward long-term sustainability and growth continues to strengthen financial position through focused allocation of capital, the receipt of a planned milestone payment, the transfer of sponsorship for NANORAY-312, and an amendment to the global licensing agreement for JNJ-1900 (NBTXR3)Curadigm, a next generation nanotherapeutic platform designed to reshape drug design and development across multiple therapeutic classes and disease areas, has launchedCash r

      4/2/25 4:15:00 PM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

      PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 20, 2025Time: 5:00 pm EDT / 11:00 pm CESTLocation: New York, NYPresenters: Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here The fireside chats will be webcast live from the eve

      5/12/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

      Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]Median Local Progression-Free Survival of 13.3 months from completion of radiationNotable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutational burden (cTMB) and LPFS and OSCA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS First patient injected in a new cohort that adds standard-of-care concurre

      5/5/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

      Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CESTNanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expa

      4/30/25 2:00:00 AM ET
      $NBTX
      Biotechnology: Pharmaceutical Preparations
      Health Care